Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283556 · ClinicalTrials.gov registry record · Phase 1
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
A Phase 1 study, sponsored by Kentuckiana Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00283556 is a Phase 1 study that has completed, run by Kentuckiana Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00283556, a Phase 1 study, has completed, sponsored by Kentuckiana Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
Interventions
- DRUG Irinotecan (Camptosar, CPT-11)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283556
The ClinicalTrials.gov registry entry for NCT00283556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kentuckiana Cancer Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan (Camptosar, CPT-11) is the first listed.
NCT00283556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283556 about?
NCT00283556 is a clinical study titled "High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma". The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
What is the current status of trial NCT00283556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2001-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00283556?
The interventions under investigation include: Irinotecan (Camptosar, CPT-11) (DRUG).
Who is sponsoring clinical trial NCT00283556?
This trial is sponsored by Kentuckiana Cancer Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.